Rate My Professor Judith Trotman

Professor Judith Trotman is a Clinical Professor in the Concord Clinical School within the Faculty of Medicine and Health at the University of Sydney. Affiliated with Concord Repatriation General Hospital, she is a haematologist who trained in New Zealand, Australia, and France, holding qualifications MBChB, FRACP, and FRCPA. She founded and directed the Clinical Research Unit at Concord from 2004 to 2019, cultivating a research-oriented environment to deliver world-class patient care. From 2019 to 2024, she served as Head of the Haematology Department. Trotman provides global leadership as Scientific Chair of the Australasian Leukaemia and Lymphoma Group, advancing clinical trials in blood cancers.

Her research specializations encompass lymphoma management, including the development of new therapies, PET scanning for response assessment, and empowering patient voices in research. She is the founding chair of Women in Lymphoma, an international alliance to build female leadership in lymphoma care and research, and a board member of the Foundation for A Bloody Great Cause. Major awards include the 2022 Peter Bing Humanitarian Award for extraordinary service to patients with Waldenström macroglobulinaemia and the 2019 Pride of Concord Award. Key publications feature the consensus paper 'Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group' (2014), 'Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma' (2016), 'Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA)' (2017), 'A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study' (2020), 'Long-term outcome of peripheral T-cell lymphomas' (2024), and 'Metabolic tumor volume predicts outcome in advanced stage follicular lymphoma' (2023). Her contributions influence international guidelines and trial designs, enhancing precision in lymphoma treatment.